JDRF and Becton, Dickinson and Co. or BD (BDX: Quote) extended their existing collaboration focused on Type 1 diabetes or T1D to accelerate the development of BD's proprietary glucose-sensing technology which has shown promise in providing very accurate and reliable continuous glucose information. JDRF and Helmsley Charitable Trust or HCT joined forces to support novel technologies that would be essential for developing fully automated artificial pancreas systems with advanced monitoring capabilities.
The research expansion is part of the JDRF-HCT Sensor Initiative designed to accelerate the development of advanced sensors that improve the detection of changing glucose levels.
"While we continue to search for the elusive cure, we must give people with T1D better tools to ease the burden of managing their disease, and this project is a step forward toward that goal," said David Panzirer, Trustee, The Helmsley Charitable Trust.
Click here to receive FREE breaking news email alerts for Becton, Dickinson and Company and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com